Skip to main content

Advertisement

Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

Fig. 3

Kaplan-Meier curves for the three arms of the phase II randomization cohort. a Kaplan-Meier progression-free survival curves between the three arms of the phase II randomization cohort. b Kaplan-Meier overall survival curves between the three arms of the phase II randomization cohort. G, gemcitabine; M, MK-0646; E, erlotinib

Back to article page